Amorchem is a private equity and venture capital firm established in 1997 and based in Montreal, Canada. The firm focuses on investing in the life sciences sector, particularly in genomics, biotechnology, and therapeutics for diseases such as cancer, infectious diseases, inflammation, and diabetes. Amorchem primarily targets promising life science projects originating from universities and research centers in Quebec, employing an innovative model that finances research-stage projects to achieve pre-clinical proof-of-concept. The firm invests in various forms, including common stock and convertible securities, and often seeks a Board seat to actively participate in the growth of its portfolio companies. Amorchem's investment strategy emphasizes both early-stage and later-stage financing, and while it may act as a sole investor, it generally prefers to engage in syndicated deals. The firm primarily operates in Canada, the United States, and Europe, with a commitment to maximizing the commercial potential of quality academic research.
Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.
SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).
SpecificiT Pharma Inc., a privately held biopharmaceutical company focused on developing innovative personalized cancer immunotherapies.
SpecificiT is developing cellular therapies for hematological cancers which to date, cannot be treated with chimeric antigen receptor modified T cells (CAR-T) therapies.
SpecificiT’s unique approach is centered on the use of Minor Histocompatability Antigens (“MiHAs”) which enable donor T-cells to be safely directed to eliminate cancer cells in a patient.
Osprey Pharmaceuticals USA, Inc. develops protein therapeutics for the treatment of inflammatory and immune diseases. Its pipeline of fusion protein therapeutics includes leukocyte population modulators that target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases. The company's lead candidate CCL2-LPM targets the CCR2 chemokine receptor expressed by pathologically activated leukocytes is for the treatment of IgA nephropathy, an inflammatory kidney disease. Osprey Pharmaceuticals USA, Inc. was founded in 2008 and is based in San Francisco, California.
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
Osprey Pharmaceuticals USA, Inc. develops protein therapeutics for the treatment of inflammatory and immune diseases. Its pipeline of fusion protein therapeutics includes leukocyte population modulators that target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases. The company's lead candidate CCL2-LPM targets the CCR2 chemokine receptor expressed by pathologically activated leukocytes is for the treatment of IgA nephropathy, an inflammatory kidney disease. Osprey Pharmaceuticals USA, Inc. was founded in 2008 and is based in San Francisco, California.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
NewBiotics transforms drug resistances into therapeutic advantages. It focuses on the discovery and development of drug molecules that leverage the cycle of drug resistance in both cancer and infectious diseases. NewBiotics is a U.S.-based company that was founded in 1997 and the company was acquired by Celmed Biosciences on June 7, 2004.
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
LymphoSign is a pharmaceutical company that is focused on the development of drugs for blood cancers. LymphoSign was acquired by Aegera Therapeutics in August 2007. LymphoSign was founded in 2000 and is based in Markham, Canada.
IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Interomex Biopharmaceuticals Inc. is dedicated to the identification of novel biological targets in key cellular processes with the aim of discovering lead compounds for the treatment of disease. The company’s proprietary Repressed Trans-activator (RTATM) technology can be used to detect protein-protein interactions between a host and an infectious agent, as well as within cells in normal and diseased states. A particular advantage of RTATM is its ability to detect the interactions of transcription transactivator proteins, which are key control points in viral infections and cell activation.
NewBiotics transforms drug resistances into therapeutic advantages. It focuses on the discovery and development of drug molecules that leverage the cycle of drug resistance in both cancer and infectious diseases. NewBiotics is a U.S.-based company that was founded in 1997 and the company was acquired by Celmed Biosciences on June 7, 2004.
Elitra Pharmaceuticals
Venture Round in 2000
Elitra Pharmaceuticals in San Diego, CA is a private company categorized under Pharmaceutical Preparations. It was established in 1997 and incorporated in California.
Developer of drugs for medical needs. Company develops novel pharmaceuticals through the company's technology access programs and therapeutic programs.
Ceptyr, Inc was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored niche in pharmaceutical development.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.
Copernicus Therapeutics, Inc. (CTI) is a clinical stage biopharmaceutical company and a leader in the emerging field of precision medicine and gene therapy. Through their proprietary, non-viral, nucleic acid nanoparticle platform, they are able to achieve robust gene transfer in several tissues without the immune response and limited treatment window of AAV.
Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.
MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.
Gene Logic is a leading integrated genomics company providing comprehensive Genomic Reference Databases and GLP compliant Microarray Services. Over 2/3rd of the top 25 Pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred genomics partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets & biomarkers.